Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another. The agreement with Gilead ...

Sanofi informed the company that KT-485/SAR447971, which is an oral, highly potent and selective development candidate targeting IRAK4 for immuno-inflammatory diseases that Kymera Therapeutics ...

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

France's Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in the US, saying it intends to spend "at least $20 billion" there by the ...

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

The US Food and Drug Administration(FDA) has granted Fast Track designation to two non-mRNA combination vaccine candidates put forward by Sanofi.

See the latest Sanofi SA ADR stock price (SNY:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Check out our SNY stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.

Find the latest Kymera Therapeutics, Inc. (KYMR) stock quote, history, news and other vital information to help you with your stock trading and investing.